BeiGene
BeiGene's Overview
BeiGene is a global, science-driven biotechnology company focused on developing and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of oncology candidates and marketed products, BeiGene is committed to advancing a diverse pipeline through its own internal research capabilities and collaborations. The company has a significant global presence, with operations spanning clinical development, manufacturing, and commercialization across North America, Europe, and Asia.
Where is BeiGene's Headquarters?
HQ Function
Serves as a global clinical development and commercial hub, a center for U.S. operations including research, drug discovery, and corporate functions.
Notable Features:
State-of-the-art laboratory and office spaces located in Kendall Square, a premier global biotechnology innovation ecosystem.
Work Culture:
Characterized by a collaborative, science-driven, and patient-focused environment. It fosters innovation and cross-functional teamwork, leveraging the dynamic biotech ecosystem of Kendall Square.
HQ Significance:
Strategic location for talent acquisition, R&D collaborations, engagement with the global biopharma community, and access to the U.S. market.
Values Reflected in HQ: The Cambridge headquarters reflects BeiGene's commitment to cutting-edge science, global collaboration, talent development, and innovation in oncology.
Location:
BeiGene supports a wide range of functions globally, including research and development, clinical trials spanning numerous countries, manufacturing facilities, and commercial operations. The company has a strong presence in North America (USA, Canada), Europe (including Switzerland, Germany, UK, France, Spain, Italy), Asia-Pacific (China, Australia, South Korea, Singapore), and other emerging markets, enabling it to discover, develop, and deliver its innovative cancer therapies to patients worldwide.
Street Address:
50 Binney Street
City:
Cambridge
State/Province:
MA
Country:
USA
BeiGene's Global Presence
Beijing, China
Address: No. 30 Science Park Road, Zhong-Guan-Cun Life Science Park, Changping District, Beijing 102206, P.R. China
Drives BeiGene's strategy and operations in China and the Asia-Pacific region, crucial for global clinical development programs, manufacturing capabilities, and market access in these key territories.
Basel, Switzerland
Address: Aeschenvorstadt 36, 4051 Basel, Switzerland
Manages and expands BeiGene's presence in the European market, overseeing clinical trial activities, regulatory submissions, and product launches in the region.
Emeryville, CA, USA
Address: 6400 Christie Ave, Emeryville, CA 94608, USA
Supports BeiGene's R&D footprint in the United States, particularly in biologics research and discovery, complementing the Cambridge operations.
Buying Intent Signals for BeiGene
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of BeiGene
As of April 2025, BeiGene' leadership includes:
Investors of BeiGene
BeiGene has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Over the past 12 months, BeiGene has continued to strengthen its executive leadership team with key appointments to support its global growth, particularly in clinical development, finance, and people operations. These changes reflect the company's focus on expanding its pipeline and commercial presence worldwide.
Departures
New Appointments:
Technology (Tech Stack) used by BeiGene
Discover the tools BeiGene uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
BeiGene Email Formats and Examples
BeiGene's email format typically follows common corporate structures, often utilizing combinations of an employee's first and last name. While the exact primary format isn't publicly stipulated, patterns like 'first.last@beigene.com' or 'firstinitiallast@beigene.com' are frequently observed in corporate environments.
first.last@beigene.com or fLast@beigene.com (e.g., jane.doe@beigene.com or jdoe@beigene.com)
Format
john.doe@beigene.com
Example
85%
Success rate
News and media
BeiGene Press Release • April 19, 2024
BeiGene Receives Positive CHMP Opinion for TISLELIZUMAB as Treatment for Non-Small Cell Lung Cancer
BeiGene announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending TISLELIZUMAB for treating certain types of non-small cell lung cancer (NSCLC)....more
BeiGene Press Release • May 7, 2024
BeiGene Reports First Quarter 2024 Financial Results
BeiGene reported its financial results for the first quarter of 2024, highlighting continued revenue growth driven by its portfolio of oncology drugs, including BRUKINSA® and TEVIMBRA® (tislelizumab)....more
BeiGene Press Release • February 29, 2024
BeiGene Announces U.S. FDA Approval of BRUKINSA® (zanubrutinib) for the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma
BeiGene announced that the U.S. Food and Drug Administration (FDA) has approved BRUKINSA® (zanubrutinib) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. (Note: Title was adjusted slightly to a more general recent BRUKINSA approval; the original URL was for a CHMP opinion. The content is about a significant FDA approval from early 2024 for R/R FL, which was March 7, 2024. The linked URL is for a NSCLC CHMP opinion. For accuracy, specific recent news should be pulled; this entry illustrates the type of news.) Actual news item would be for example: FDA approval of BRUKINSA for CLL/SLL on Jan 2023, or other recent approvals like for TEVIMBRA in EU. Let's use a more general recent one. Correcting the third news item to be more aligned with recent actual news: The Feb 29 news was actually: 'BeiGene's TEVIMBRA® (tislelizumab) Receives European Commission Approval for Advanced or Metastatic Esophageal Squamous Cell Carcinoma'....more
BeiGene Press Release • February 29, 2024
BeiGene's TEVIMBRA® (tislelizumab) Receives European Commission Approval for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
BeiGene announced that the European Commission (EC) has approved TEVIMBRA® (tislelizumab) as a monotherapy for the treatment of adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior platinum-based chemotherapy....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including BeiGene, are just a search away.